These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38976164

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Associations of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture.
    Swanson CM, Srikanth P, Lee CG, Cummings SR, Jans I, Cauley JA, Bouillon R, Vanderschueren D, Orwoll ES, Nielson CM, Osteoporotic Fractures in Men MrOS Study Research Group.
    J Bone Miner Res; 2015 Aug; 30(8):1403-13. PubMed ID: 25707402
    [Abstract] [Full Text] [Related]

  • 23. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.
    J Clin Oncol; 2008 Oct 20; 26(30):4875-82. PubMed ID: 18725648
    [Abstract] [Full Text] [Related]

  • 24. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2018 Nov 20; 36(6):716-722. PubMed ID: 29116414
    [Abstract] [Full Text] [Related]

  • 25. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD.
    J Bone Miner Res; 2000 Aug 20; 15(8):1526-36. PubMed ID: 10934651
    [Abstract] [Full Text] [Related]

  • 26. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC, Intergroup Exemestane Study group.
    Lancet Oncol; 2007 Feb 20; 8(2):119-27. PubMed ID: 17267326
    [Abstract] [Full Text] [Related]

  • 27. Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19.
    Kazemi-Sufi S, Alipour S, Rabieepour M, Roshan-Milani S, Naderi R.
    BMC Infect Dis; 2024 Sep 27; 24(1):1047. PubMed ID: 39333916
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
    Rhee Y, Song K, Park S, Park HS, Lim SK, Park BW.
    Endocr J; 2013 Sep 27; 60(2):167-72. PubMed ID: 23064476
    [Abstract] [Full Text] [Related]

  • 29. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S, Carly B, Liebens F, Antoine C.
    Maturitas; 2009 Sep 20; 64(1):1-3. PubMed ID: 19709824
    [Abstract] [Full Text] [Related]

  • 30. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
    Bassatne A, Bou Khalil A, Chakhtoura M, Arabi A, Van Poznak C, El-Hajj Fuleihan G.
    Metabolism; 2022 Mar 20; 128():154962. PubMed ID: 34958816
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women.
    Hernández JL, Olmos JM, Romaña G, Llorca J, Martínez J, Castillo J, de Juan J, Pérez-Pajares I, Ruiz S, González-Macías J.
    J Clin Endocrinol Metab; 2014 Sep 20; 99(9):3304-9. PubMed ID: 24878047
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I, Rosado Sierra JA, Pérez Blanco C, Modroño Móstoles N, Guijarro de Armas G, Navea Aguilera C.
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb 20; 66(2):108-116. PubMed ID: 30077631
    [Abstract] [Full Text] [Related]

  • 35. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M, Clotfelter A, Poznak CV.
    Clin Breast Cancer; 2009 May 20; 9(2):72-6. PubMed ID: 19433386
    [Abstract] [Full Text] [Related]

  • 36. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R, Monteverdi S, Mazziotti G, Amoroso V, Roca E, Maffezzoni F, Vassalli L, Rodella F, Formenti AM, Frara S, Maroldi R, Berruti A, Simoncini E, Giustina A.
    Bone; 2017 Apr 20; 97():147-152. PubMed ID: 28104509
    [Abstract] [Full Text] [Related]

  • 37. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
    Pedersini R, Amoroso V, Maffezzoni F, Gallo F, Turla A, Monteverdi S, Ardine M, Ravanelli M, Vassalli L, Rodella F, Formenti AM, Dalla Volta A, Simoncini EL, Giustina A, Maroldi R, Berruti A.
    JAMA Netw Open; 2019 Sep 04; 2(9):e1911080. PubMed ID: 31560383
    [Abstract] [Full Text] [Related]

  • 38. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS.
    Osteoporos Int; 2017 Apr 04; 28(4):1413-1422. PubMed ID: 28083668
    [Abstract] [Full Text] [Related]

  • 39. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression.
    Rabenda V, Bruyère O, Reginster JY.
    Osteoporos Int; 2011 Mar 04; 22(3):893-901. PubMed ID: 21060990
    [Abstract] [Full Text] [Related]

  • 40. Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
    Catalano A, Morabito N, Agostino RM, Basile G, Gaudio A, Atteritano M, Natale G, Xourafa A, Morini E, Adamo V, Lasco A.
    Menopause; 2017 Jan 04; 24(1):85-91. PubMed ID: 27575547
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.